Oncternal Therapeutics (ONCT) Short Interest Ratio & Short Volume $0.53 0.00 (0.00%) As of 02/14/2025 Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Oncternal Therapeutics Short Interest DataOncternal Therapeutics (ONCT) has a short interest of 14,200 shares, representing 0.54% of the float (the number of shares available for trading by the public). This marks a -68.72% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 45,347 shares to cover all short positions.Current Short Interest14,200 sharesPrevious Short Interest45,400 sharesChange Vs. Previous Month-68.72%Dollar Volume Sold Short$16,188.00Short Interest Ratio0.1 Days to CoverLast Record DateNovember 15, 2024Outstanding Shares2,960,000 sharesFloat Size2,650,000 sharesShort Percent of Float0.54%Today's Trading Volume0 sharesAverage Trading Volume45,347 sharesToday's Volume Vs. Average0% Short Selling Oncternal Therapeutics? Sign up to receive the latest short interest report for Oncternal Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartONCT Short Interest Over TimeONCT Days to Cover Over TimeONCT Percentage of Float Shorted Over Time Oncternal Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/15/202414,200 shares $16,188.00 -68.7%0.5%0.1 $1.14 10/31/202445,400 shares $66,284.00 +168.6%1.7%0.5 $1.46 10/15/202416,900 shares $20,449.00 -5.6%0.6%0.2 $1.21 9/30/202417,900 shares $23,628.00 -26.0%0.7%0.4 $1.32 9/15/202424,200 shares $35,332.00 +79.3%0.9%0.8 $1.46 8/31/202413,500 shares $55,497.15 -12.3%0.5%1.6 $4.11 8/15/202415,400 shares $58,520.00 -12.0%0.6%1.8 $3.80 7/31/202417,500 shares $113,750.00 -17.8%0.7%2.8 $6.50 7/15/202421,300 shares $163,371.00 +4.4%0.8%3.7 $7.67 6/30/202420,400 shares $155,040.00 +1.0%0.8%3.2 $7.60 Get the Latest News and Ratings for ONCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 6/15/202420,200 shares $177,438.82 -3.4%0.8%3.4 $8.78 5/31/202420,900 shares $192,489.00 -9.5%0.8%3.4 $9.21 5/15/202423,100 shares $204,204.00 +77.7%0.9%3.3 $8.84 4/30/202413,000 shares $108,032.60 -5.8%0.5%1.8 $8.31 4/15/202413,800 shares $121,440.00 -17.4%0.5%1.5 $8.80 3/31/202416,700 shares $150,300.00 +11.3%0.6%1.3 $9.00 3/15/202415,000 shares $120,300.00 -6.3%0.6%1 $8.02 2/29/202416,000 shares $148,800.00 -28.3%0.6%0.9 $9.30 2/15/202422,300 shares $200,477.00 -10.8%0.8%1.3 $8.99 1/31/202425,000 shares $244,250.00 +25.0%0.9%1.5 $9.77 1/15/202420,000 shares $171,800.00 +52.7%0.8%1.2 $8.59 12/31/202313,100 shares $140,484.40 -94.6%0.4%0.9 $10.72 12/15/2023241,400 shares $91,732.00 -22.1%N/A1 $0.38 11/30/2023310,000 shares $114,080.00 -28.6%N/A1.7 $0.37 11/15/2023433,900 shares $140,974.11 +5.5%N/A2.9 $0.32 10/31/2023411,200 shares $139,561.28 +46.7%N/A2.5 $0.34 10/15/2023280,300 shares $82,688.50 +2.1%N/A1.7 $0.30 9/30/2023274,500 shares $82,350.00 -8.0%N/A1.4 $0.30 9/15/2023298,300 shares $104,405.00 +0.6%N/A1.4 $0.35 8/31/2023296,500 shares $88,950.00 -7.6%N/A1.2 $0.30 8/15/2023320,900 shares $120,979.30 -6.4%N/A1.2 $0.38 7/31/2023342,700 shares $126,901.81 -23.6%N/A1.3 $0.37 7/15/2023448,600 shares $205,593.38 +32.8%N/A1.7 $0.46 6/30/2023337,700 shares $116,506.50 -4.0%N/A0.9 $0.35 6/15/2023351,600 shares $140,640.00 +27.4%N/A0.6 $0.40 5/31/2023276,100 shares $78,688.50 +7.4%N/A0.5 $0.29 5/15/2023257,000 shares $75,815.00 -46.6%N/A0.5 $0.30 4/30/2023480,900 shares $147,395.85 -1.9%N/A0.9 $0.31 4/15/2023490,300 shares $153,120.69 +29.0%N/A1 $0.31 3/31/2023380,000 shares $298,300.00 -8.0%N/A0.8 $0.79New powers for Elon (Ad)According to one Boston think tank, which has connections in almost every major Wall Street institution, Elon may be planning something huge. It could have a dramatic impact on the stock market, in the very near future.Here's everything you need to know. 3/15/2023412,900 shares $300,426.04 +1.8%N/A1.8 $0.73 2/28/2023405,600 shares $361,632.96 -2.1%N/A1.5 $0.89 2/15/2023414,200 shares $426,626.00 -5.6%N/A1.6 $1.03 1/31/2023438,600 shares $491,232.00 -34.3%N/A1.6 $1.12 1/15/2023667,600 shares $861,204.00 -29.7%N/A2.4 $1.29 12/30/2022950,000 shares $950,000.00 +0.2%N/A3.4 $1.00 12/15/2022947,800 shares $871,976.00 +61.3%N/A3.4 $0.92 11/30/2022587,700 shares $534,865.77 -18.2%N/A2.1 $0.91 11/15/2022718,800 shares $725,988.00 +28.0%N/A2.8 $1.01 10/31/2022561,400 shares $589,470.00 -15.6%N/A1.7 $1.05 10/15/2022665,300 shares $725,177.00 -52.1%N/A1.8 $1.09 9/30/20221,390,000 shares $1.24 million +70.0%N/A3.3 $0.89 9/15/2022817,800 shares $801,525.78 +38.2%1.7%1.6 $0.98 8/31/2022591,800 shares $662,816.00 +7.4%1.3%1.1 $1.12 8/15/2022551,100 shares $677,853.00 -16.3%1.3%0.5 $1.23 7/31/2022658,400 shares $678,152.00 -1.9%1.5%0.6 $1.03 7/15/2022671,200 shares $771,880.00 -11.1%1.5%0.6 $1.15 6/30/2022754,800 shares $837,828.00 -66.2%8.5%0.7 $1.11 6/15/20222,230,000 shares $2.65 million -3.9%25.2%2.2 $1.19 5/31/20222,320,000 shares $3.43 million +14.3%5.4%2.6 $1.48 5/15/20222,030,000 shares $1.42 million -6.5%4.7%6.5 $0.70 4/30/20222,170,000 shares $1.85 million +4.3%5.0%7.3 $0.85 4/15/20222,080,000 shares $2.39 million +0.5%4.8%6.6 $1.15 3/31/20222,070,000 shares $2.88 million +0.5%4.8%5.7 $1.39 3/15/20222,060,000 shares $2.93 million +1.0%4.8%3.8 $1.42 2/28/20222,040,000 shares $3.73 million +0.5%4.7%3.5 $1.83 2/15/20222,030,000 shares $4.12 million -7.3%4.7%3.2 $2.03 1/31/20222,190,000 shares $4.10 million +6.3%5.5%3.2 $1.87 1/15/20222,060,000 shares $4.18 million +66.1%4.8%3 $2.03 12/31/20211,240,000 shares $2.81 million -6.8%2.9%1.9 $2.27 12/15/20211,330,000 shares $3.39 million -5.7%3.1%2.5 $2.55 11/30/20211,410,000 shares $4.16 million +6.8%3.2%2.8 $2.95 11/15/20211,320,000 shares $5.10 million -12.0%3.0%2.6 $3.86 10/29/20211,500,000 shares $5.51 million -3.9%3.5%2.8 $3.67 10/15/20211,560,000 shares $6.04 million -8.2%3.6%2.9 $3.87 9/30/20211,700,000 shares $7.09 million -11.5%3.9%2.7 $4.17 9/15/20211,920,000 shares $8.01 million -2.0%4.4%2.5 $4.17 8/31/20211,960,000 shares $8.86 million +15.3%4.5%2.4 $4.52 8/13/20211,700,000 shares $6.27 million -6.6%3.9%1.9 $3.69 7/30/20211,820,000 shares $7.10 million +0.6%4.2%1.8 $3.90 7/15/20211,810,000 shares $7.53 million -33.9%4.2%1.6 $4.16 6/30/20212,740,000 shares $13.02 million +115.8%6.3%2.3 $4.75 6/15/20211,270,000 shares $6.73 million +0.8%2.9%0.9 $5.30 5/28/20211,260,000 shares $7.17 million +17.8%2.9%0.8 $5.69 5/14/20211,070,000 shares $5.33 million +14.7%N/A0.7 $4.98 4/30/2021932,600 shares $6.02 million +76.9%N/A0.6 $6.46 4/15/2021527,200 shares $3.30 million +116.9%N/A0.3 $6.26 3/31/2021243,100 shares $1.96 million +15.1%N/A0.1 $8.08 3/15/2021211,300 shares $1.60 million +136.6%N/A0.1 $7.57 2/26/202189,300 shares $604,561.00 -14.2%N/A0 $6.77New powers for Elon (Ad)According to one Boston think tank, which has connections in almost every major Wall Street institution, Elon may be planning something huge. It could have a dramatic impact on the stock market, in the very near future.Here's everything you need to know. 2/12/2021104,100 shares $733,905.00 -23.1%N/A0 $7.05 1/29/2021135,300 shares $730,620.00 -15.9%N/A0 $5.40 1/15/2021160,800 shares $913,344.00 -21.5%N/A0 $5.68 12/31/2020204,700 shares $984,607.00 -46.8%N/A0 $4.81 12/15/2020384,900 shares $1.94 million +104.5%N/A0.1 $5.04 11/30/2020188,200 shares $502,494.00 -85.6%N/A0 $2.67 11/15/20201,310,000 shares $5.95 million +13,545.8%N/A0.5 $4.54 10/30/20209,600 shares $14,880.00 -62.9%N/A0 $1.55 10/15/202025,900 shares $45,843.00 +69.3%0.2%0.3 $1.77 9/30/202015,300 shares $26,010.00 -69.2%0.1%0.2 $1.70 9/15/202049,600 shares $105,648.00 -17.6%0.4%0.5 $2.13 8/31/202060,200 shares $128,226.00 +64.5%0.4%0.7 $2.13 8/14/202036,600 shares $101,748.00 -25.0%0.3%0.5 $2.78 7/31/202048,800 shares $139,080.00 +41.9%0.4%0.7 $2.85 7/15/202034,400 shares $98,040.00 -7.5%0.3%0.6 $2.85 6/30/202037,200 shares $107,880.00 +19.2%0.3%0.9 $2.90 6/15/202031,200 shares $86,424.00 +26.8%0.3%0.9 $2.77 5/29/202024,600 shares $71,340.00 +30.9%0.2%1.1 $2.90 5/15/202018,800 shares $57,528.00 -0.5%0.2%1 $3.06 4/30/202018,900 shares $60,291.00 +2.2%0.2%1.5 $3.19 4/15/202018,500 shares $46,250.00 -7.0%0.2%1.3 $2.50 3/31/202019,900 shares $53,929.00 -74.0%0.2%1.3 $2.71 3/13/202076,500 shares $214,200.00 -7.6%0.8%4.6 $2.80 2/28/202082,800 shares $206,172.00 +5.6%0.8%4.5 $2.49 ONCT Short Interest - Frequently Asked Questions What is Oncternal Therapeutics' current short interest? Short interest is the volume of Oncternal Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, investors have sold 14,200 shares of ONCT short. 0.54% of Oncternal Therapeutics' shares are currently sold short. Learn More on Oncternal Therapeutics' current short interest. Which institutional investors are shorting Oncternal Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Oncternal Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Oncternal Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.54% of Oncternal Therapeutics' floating shares are currently sold short. Is Oncternal Therapeutics' short interest increasing or decreasing? Oncternal Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 14,200 shares, a decrease of 68.7% from the previous total of 45,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Oncternal Therapeutics' float size? Oncternal Therapeutics currently has issued a total of 2,960,000 shares. Some of Oncternal Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Oncternal Therapeutics currently has a public float of 2,650,000 shares. How does Oncternal Therapeutics' short interest compare to its competitors? 0.54% of Oncternal Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oncternal Therapeutics: Aptorum Group Limited (2.07%), Virax Biolabs Group Limited (1.46%), Clearmind Medicine Inc. (10.97%), Soligenix, Inc. (4.82%), Organovo Holdings, Inc. (0.47%), ABVC BioPharma, Inc. (1.98%), Alzamend Neuro, Inc. (1.51%), Elevai Labs, Inc. (10.91%), SciSparc Ltd. (1.90%), IM Cannabis Corp. (0.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($4.85 billion), Charter Communications, Inc. ($4.81 billion), International Paper ($2.96 billion), Cencora, Inc. ($2.40 billion), Paychex, Inc. ($2.38 billion), Lululemon Athletica Inc. ($2.05 billion), SoFi Technologies, Inc. ($2.03 billion), Live Nation Entertainment, Inc. ($1.93 billion), Onsemi ($1.82 billion), and Tractor Supply ($1.65 billion). View all of the most shorted stocks. What does it mean to sell short Oncternal Therapeutics stock? Short selling ONCT is an investing strategy that aims to generate trading profit from Oncternal Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oncternal Therapeutics? A short squeeze for Oncternal Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ONCT, which in turn drives the price of the stock up even further. How often is Oncternal Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ONCT, twice per month. The most recent reporting period available is November, 15 2024. More Short Interest Resources from MarketBeat Related Companies Aptorum Group Short Interest Virax Biolabs Group Short Interest Clearmind Medicine Short Interest Soligenix Short Interest Organovo Short Interest ABVC BioPharma Short Interest Alzamend Neuro Short Interest Elevai Labs Short Interest SciSparc Short Interest IM Cannabis Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ONCT) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredNvidia Is About to Shock the World: March 17thIf you have money in any artificial intelligence stock or are interested in AI… Mark this date on your cale...Brownstone Research | SponsoredThe Elon Coup?According to an extremely well connected group of financial forecasters (with connections in the Pentagon and ...Altimetry | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredHow You Could Invest in Elon’s ‘Final Move’What if I told you Elon Musk's next big venture could leave Tesla and SpaceX in the dust? It may sound unbe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
